Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

1.

Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.

Mann JF, Yi QL, Sleight P, Dagenais GR, Gerstein HC, Lonn EM, Bosch J; HOPE Investigators..

Clin Nephrol. 2005 Mar;63(3):181-7.

PMID:
15786818
2.

The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.

Heerspink HJ, Gao P, de Zeeuw D, Clase C, Dagenais GR, Sleight P, Lonn E, Teo KT, Yusuf S, Mann JF.

Eur J Prev Cardiol. 2014 Mar;21(3):299-309. doi: 10.1177/2047487313510678.

PMID:
24191305
3.

Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S.

Ann Intern Med. 2001 Apr 17;134(8):629-36.

PMID:
11304102
4.

The HOPE Study (Heart Outcomes Prevention Evaluation).

Sleight P.

J Renin Angiotensin Aldosterone Syst. 2000 Mar;1(1):18-20. Review.

PMID:
11967789
5.

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators.

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G.

N Engl J Med. 2000 Jan 20;342(3):145-53. Erratum in: 2000 May 4;342(18):1376. N Engl J Med 2000 Mar 9;342(10):748.

7.

Effect of long-term therapy with ramipril in high-risk women.

Lonn E, Roccaforte R, Yi Q, Dagenais G, Sleight P, Bosch J, Suhan P, Micks M, Probstfield J, Bernstein V, Yusuf S; HOPE Investigators. Heart Outcomes Prevention Evaluation..

J Am Coll Cardiol. 2002 Aug 21;40(4):693-702.

8.

Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.

Mann JF, Gerstein HC, Pogue J, Lonn E, Yusuf S.

Am J Cardiovasc Drugs. 2002;2(3):157-62. Review.

PMID:
14727978
9.

Diabetes and the HOPE study: implications for macrovascular and microvascular disease.

Gerstein HC.

Int J Clin Pract Suppl. 2001 Jan;(117):8-12.

PMID:
11715357
10.

Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.

Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S; Heart Outcomes Prevention Evaluation (HOPE) Investigators..

Circulation. 2001 Oct 2;104(14):1615-21.

11.

Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.

Teo KK, Mitchell LB, Pogue J, Bosch J, Dagenais G, Yusuf S; HOPE Investigators..

Circulation. 2004 Sep 14;110(11):1413-7.

12.
14.
15.

Spotlight on ramipril in the prevention of cardiovascular outcomes.

Warner GT, Perry CM.

Am J Cardiovasc Drugs. 2003;3(2):113-6. Review.

PMID:
14727938
16.
17.

[The HOPE Study. What does it contribute to general practice?].

Mann J, Sleight P.

MMW Fortschr Med. 2000 Nov 23;142(47):28-32. German.

PMID:
11143776
20.

Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.

Chu CS, Cheng KH, Lee KT, Lin TH, Lee ST, Su HM, Voon WC, Sheu SH, Lai WT.

Kaohsiung J Med Sci. 2005 Nov;21(11):511-6.

Supplemental Content

Support Center